On February 5, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death ……
On January 27, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult patients with unres……
January 23, 2025 -- Eisai and Biogen have announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for LEQEMBI? (lecanemab-irmb) subcutaneous autoinjector (SC-AI) fo……
December 20, 2024 -- Novo Nordisk announced that the FDA approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 22 ……
December 4, 2024 -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound? (tirzepatide) provided a 47% greater relative weight loss……
November 22, 2024 – UCB announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX? (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).2 BI……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
